Skip to main content
Toggle navigation
Login
Search
Home
Tweets by 2023 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Speaker
Home
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Albiges, Laurence
Institut Gustave Roussy
Debate: In favour of IO-TKI Doublets
Laurence Albiges
Favorite
Debate: In favour of IO-TKI Triplets
Location: Lenox 3
Laurence Albiges
Favorite
Introduction to Session 7
Location: Lenox 3
Laurence Albiges
Favorite
KCA Updates
Location: Lenox 3
Laurence Albiges
Favorite
Session 7 Q&A
Location: Lenox 3
Laurence Albiges
Favorite
SESSION 7: BEYOND FIRST-LINE THERAPY
Location: Lenox 3
Laurence Albiges
Favorite
WOMEN IN RCC -SPONSORED BY EISAI
Location: Lenox 2
Laurence Albiges
Favorite
Algaba Arrea, Ferran
Fundacio Puigvert. Universitat Autònoma de Barcelona-Spain
WHO pathological classification: Present and Future
Location: Lenox 3
Ferran Algaba Arrea
Favorite
Atkins, Michael
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Oral Abstract: Cross-trial propensity score weighted analysis of nivolumab plus ipilimumab versus nivolumab monotherapy for patients with untreated advanced renal cell carcinoma
Location: Lenox 3
Michael Atkins
Favorite
Debate: In favour of IO-IO
Location: Lenox 3
Michael Atkins
Favorite
Phase II study of nivolumab and salvage nivolumab + ipilimumab in RCC (HCRN GU16-260): Correlative Results
Michael Atkins
Favorite
Session 9 Q&A
Location: Lenox 3
Michael Atkins
Favorite
SESSION 9: PROGRESS IN THE TREATMENT OF VARIANT HISTOLOGY RCC
Location: Lenox 3
Michael Atkins
Favorite
YI - Academic Opportunities
Location: Lenox 2
Michael Atkins
Favorite